Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
- 1 September 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (17) , 11214-11224
- https://doi.org/10.1128/jvi.79.17.11214-11224.2005
Abstract
Human immunodeficiency virus type 1 (HIV-1) is a difficult target for vaccine development, in part because of its ever-expanding genetic diversity and attendant capacity to escape immunologic recognition. Vaccine efficacy might be improved by maximizing immunogen antigenic similarity to viruses likely to be encountered by vaccinees. To this end, we designed a prototype HIV-1 envelope vaccine using a deduced ancestral state for the env gene. The ancestral state reconstruction method was shown to be >95% accurate by computer simulation and 99.8% accurate when estimating the known inoculum used in an experimental infection study in rhesus macaques. Furthermore, the deduced ancestor gene differed from the set of sequences used to derive the ancestor by an average of 12.3%, while these latter sequences were an average of 17.3% different from each other. A full-length ancestral subtype B HIV-1 env gene was constructed and shown to produce a glycoprotein of 160 kDa that bound and fused with cells expressing the HIV-1 coreceptor CCR5. This Env was also functional in a virus pseudotype assay. When either gp160- or gp140-expressing plasmids and recombinant gp120 were used to immunize rabbits in a DNA prime-protein boost regimen, the artificial gene induced immunoglobulin G antibodies capable of weakly neutralizing heterologous primary HIV-1 strains. The results were similar for rabbits immunized in parallel with a natural isolate, HIV-1 SF162. Further design efforts to better present conserved neutralization determinants are warranted.Keywords
This publication has 81 references indexed in Scilit:
- Demographic Factors That Influence the Neutralizing Antibody Response in Recipients of Recombinant HIV‐1 gp120 VaccinesThe Journal of Infectious Diseases, 2004
- Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope GlycoproteinsJournal of Virology, 2004
- Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of SpecificitiesJournal of Virology, 2003
- Antibody neutralization and escape by HIV-1Nature, 2003
- HIV-1 Diversity and Vaccine DevelopmentScience, 2002
- HIV Type 1 Variants Transmitted to Women in Kenya Require the CCR5 Coreceptor for Entry, Regardless of the Genetic Complexity of the Infecting VirusAIDS Research and Human Retroviruses, 2002
- Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody ResponseJournal of Virology, 2002
- Clinical Trials of HIV VaccinesAnnual Review of Medicine, 2002
- The genetic data environment an expandable GUI for multiple sequence analysisBioinformatics, 1994
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994